GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply

Lancet Diabetes Endocrinol. 2018 Oct;6(10):765. doi: 10.1016/S2213-8587(18)30239-0.

Authors

Katherine R Tuttle¹, Mark C Lakshmanan², Brian Rayner³, Robert S Busch⁴, Alan G Zimmermann², D Bradley Woodward², Fady T Botros²

Affiliations

¹ Providence Health Care, University of Washington, Spokane, WA 99204, USA. Electronic address: katherine.tuttle@providence.org.
² Eli Lilly and Company, Indianapolis, IN, USA.
³ Division of Nephrology and Hypertension, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.
⁴ Albany Medical Center Division of Community Endocrinology, Albany, NY, USA.

PMID: 30266182
DOI: 10.1016/S2213-8587(18)30239-0

No abstract available

Publication types

Letter
Comment

MeSH terms

ErbB Receptors
Glomerular Filtration Rate
Glucagon-Like Peptide-1 Receptor / agonists
Humans
Hypoglycemic Agents*
Renal Insufficiency, Chronic*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
EGFR protein, human
ErbB Receptors